readthroughSign in
Jul 2, 2026Trial update1 fact check note

Cingulate posts Phase 3 CTx-1301 classroom results in ADHD, more than two years after trial ended

A single-center Phase 3 study of dexmethylphenidate in 26 adults with ADHD has results listed, dated years after the trial finished.

This week's record for Cingulate Therapeutics centers on one Phase 3 trial gaining results after a long gap since completion.

  • CTx-1301 (dexmethylphenidate), Phase 3, adults with ADHD: the trial "NCT05631626" is listed as completed, with 26 participants actually enrolled1 in a study designed for about 25 adults. The primary and study completion dates are both listed as 2023-06-13 (actual)1, while results were first posted on 2026-07-02 (actual)1. The trial measured change on the PERMP-C test, a validated 10-minute math test that measures attention and accuracy in ADHD by counting correctly answered problems1, comparing optimized doses of 25mg to 50mg of CTx-13011 against placebo.

Fact check notes

  • ImpreciseCompared optimized doses of 25mg to 50mg of CTx-1301 against placeboOmits the intermediate 37.5mg dose arm, though the range description is not incorrect.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.